Clinical stage immuno-oncology company Imugene Limited (ASX:IMU) has received a Notice of Grant from the European Patent Office for Patent Application which protects the company’s HER-Vaxx immunotherapy, currently in development for HER-2 positive gastric cancer.
The patent titled “A VACCINE COMPOSITION AND USES THEREOF” protects the method of composition and method of use of Imugene’s HER-Vaxx immunotherapy to 2036.
Imugene’s M.D. & CEO, Ms Leslie Chong said attaining the key European patent is an important milestone and is another major pharmaceutical market to grant patent protection for HER-Vaxx until 2036.
Imugene’s HER-Vaxx is a B-cell activating immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.
The immunotherapy is constructed from several B cell epitopes derived from the extracellular domain of HER-2/neu. It has been shown in pre-clinical studies, in Phase I and now Phase 2 studies to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target.
Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours.
Its platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies.
